Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Leukemia, Myeloid, Acute 10Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Leukemia 3Multiple Myeloma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hodgkin Disease 2Gliosarcoma 2Glioblastoma 2Warts 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pinealoma 1Neutropenia 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Medulloblastoma 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma 1Leukopenia 1Leukemia, Lymphocytic, Chronic, B-Cell 1Infections 1Immunologic Deficiency Syndromes 1Hematologic Neoplasms 1Graft vs Host Disease 1Glioma 1Brain Neoplasms 1Agammaglobulinemia 1Acquired Immunodeficiency Syndrome 1

Interventions

Radiotherapy 2surufatinib 1sodium thiosulfate 1poly ICLC 1plerixafor 1adavosertib 1Vaccines 1Temozolomide 1Radiation 1Melphalan 1Mannitol 1Irinotecan 1Eflornithine 1Decitabine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neuroectodermal Tumors, Primitive × plerixafor × Clear all
NCT01977677 2018-10-23

Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma

Stanford University

Phase 1/2 Completed
30 enrolled 11 charts
CNSSarcoma

Glioblastoma, Glioma, Medulloblastoma, Pinealoma, Neuroectodermal Tumors, Primitive, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡